Big TV spender Lyrica drops off top 10 in October by Beth Snyder Bulik Monday, November 5, 2018 Is Pfizer’s Lyrica leaving the TV ad game? Facing patent expiration, the stalwart top 10 TV spender dropped its budget to $3.8 million in October.
Pharma TV ad spend beats last year, led by AbbVie and Pfizer by Beth Snyder Bulik Monday, October 15, 2018 With three quarters of pharma TV ad spending down and one to go, national media buys are tracking ahead of 2017, with brands doling out $2.81 billion.
July's big TV spenders Humira, Lyrica drop $25M each by Beth Snyder Bulik Tuesday, August 14, 2018 AbbVie’s Humira, along with Pfizer’s Lyrica and Xeljanz, each spent more than $25 million on TV advertising for July.
AbbVie, Roche, Pfizer cited for 'exploitative' patent strategy by Angus Liu Monday, August 6, 2018 AbbVie has filed for a whopping 247 patent on Humira, an example of how drugmakers try to forestall copycat competition.
AbbVie, Pfizer are becoming an item atop the ad-spend charts by Beth Snyder Bulik Wednesday, May 2, 2018 AbbVie's Humira and Pfizer's Lyrica once again rank No. 1 and No. 2 on our April list for pharma TV ad spending, according to iSpot.tv data.
No need for a megamerger, Pfizer CEO says. Our pipeline's got it by Eric Sagonowsky Tuesday, May 1, 2018 Pfizer CEO Ian Read contends that the company's pipeline is strong enough to fuel growth. In other words, don't look for a "transformative" deal.
No March madness for pharma ad spending as Humira tops list by Beth Snyder Bulik Wednesday, April 11, 2018 AbbVie’s Humira and Pfizer’s Lyrica remained in the top two spots for pharma TV ad spending in March, according to realtime TV ad tracker iSpot.tv.
Pfizer's Ibrance joins February's TV ad-spending leaders by Beth Snyder Bulik Friday, March 23, 2018 Debut ads helped drive list-toppers for pharma TV spend in February, with Ibrance, Otezla, Rexulti, Entresto and Eliquis entering the top 10.
Pfizer could face £502M bill for Lyrica in U.K.: study by Eric Sagonowsky Monday, February 26, 2018 Pfizer could be on the hook for £502 million in National Health Service spending on Lyrica if a patent appeal fails, according to a new study.
